ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting

    Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience

    Francesca De Nard1, Vittorio Grosso2, Monica Todoerti3, Carlomaurizio Montecucco4 and Roberto Caporali5, 1Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 2Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, 3Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 4Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, 5Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy

    Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
  • Abstract Number: 80 • 2014 ACR/ARHP Annual Meeting

    Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry

    Michael Kruse Meyer1, Marlene Andersen2, Grethe N. Andersen1 and Allan Stensballe3, 1Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, 2Department of Rheumatology, Aalborg University, Hjørring, Denmark, 3Health Science and Technology, Aalborg University, Aalborg, Denmark

    Background/Purpose: In this study we are analyzing leukocyte subtype responses from patients with rheumatoid arthritis (RA) to IL6 inhibition. A large contribution to RA immunopathogenesis…
  • Abstract Number: 451 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab

    Yu F. Asanuma1, Takashi Maruyama2, Maiko Yanagisawa2, Kazuhiro Yokota3, Yoshihiro Yoshida2, Hiroshi Kajiyama1, Kojiro Sato1, Yuji Akiyama1 and Toshihide Mimura4, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Saitama Medical University, Saitama, Japan, 3Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Interleukin-6 (IL-6) has been demonstrated to play a pathological role in rheumatoid arthritis (RA). IL-6 strongly induces production of C-reactive protein (CRP) and fibrinogen…
  • Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla

    Hitomi Kobayashi1,2, Isamu Yokoe3, Hiroshi Sato2, Yasuyuki Kobayashi4, Kihei Yoneyama5, Masaharu Hirano6 and Masami Takei7, 1Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 3Nihon University School of Medicine, Tokyo, Japan, 4Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, 5Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, 6Cardiology, Tokyo Medical Colleage, Tokyo, Japan, 7Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan

    Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…
  • Abstract Number: 2827 • 2013 ACR/ARHP Annual Meeting

    Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients

    Dimitrios A. Pappas1, Ani John2, Jeffrey R. Curtis3, George W. Reed4, Jeffrey D. Greenberg5, Ashwini Shewade2, Daniel H. Solomon6, Joel M. Kremer7 and Tanya Sommers4, 1Columbia University, New York, NY, 2Genentech Inc., South San Francisco, CA, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4CORRONA, Inc., Southborough, MA, 5Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: The risk for cardiovascular disease (CVD) is increased in patients (pts) with RA. The interplay between traditional CV risk factors and inflammatory burden may…
  • Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting

    Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient

    Chisa Okura1, Yukio Yonemoto2, Koichi Okamura1, Tetsuya Kaneko3, Tsutomu Kobayashi1 and Kenji Takagishi1, 1Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, 3Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan

    Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
  • Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency

    Osamu Saiki1, Hiroshi Uda1, Ayumi Matsumoto2, Aya Mizumoto3, Tamaki Harada3 and Toshirou Takama3, 1Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, 2Higashiosaka City General Hospital, Higashiosaka, Japan, 3Nephrology, Higashiosaka City General Hospital, Higashiosaka, Japan

    Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…
  • Abstract Number: 2390 • 2013 ACR/ARHP Annual Meeting

    Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.

    Cecilia Prieto- Candau1, Virginia Moreira- Navarrete2, Carmen Vargas-Lebrón2, Juan M Prieto-Martinez2, Dolores Ruiz-Montesinos2, Javier Toyos-Saenz de Miera2 and Federico Navarro-Sarabia3, 1Rheumatology, Hospital Virgen Macarena, SEVILLE, Spain, 2Rheumatology, Hospital Virgen Macarena, Seville, Spain, 3Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain

    Background/Purpose: Tocilizumab (TCZ), an anti-IL-6-receptor antibody, is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults with inadequate response or intolerance…
  • Abstract Number: 2368 • 2013 ACR/ARHP Annual Meeting

    Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group

    Ryu Watanabe1, Hiroshi Okuno2, Tomonori Ishii1, Yasuhiko Hirabayashi3 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 2Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, 3Rheumatology, Hikarigaoka Spellman Hospital, Sendai, Japan

    Background/Purpose: One of the important therapeutic goals in patients with rheumatoid arthritis (RA) is to halt radiographic progression. Tocilizumab (TCZ), an IL-6 receptor antibody, has…
  • Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting

    Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis

    Martin Soubrier1, Thomas Frayssac2, Bruno Pereira3, Marion Couderc Sr.4, Coline Daron2, Jean Jacques Dubost5, Sandrine Malochet-Guinamand4, Anne Tournadre4 and Sylvain Mathieu4, 1Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, 2CHU CLERMONT-FERRAND, Clermont-ferrand, France, 3Clinical research department, Clermont-Ferrand, France, 4Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 5Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France

    Background/Purpose:  Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and  traditional risk factors could be involved in…
  • Abstract Number: 2327 • 2013 ACR/ARHP Annual Meeting

    Dose Reduction Of Tocilizumab In Rheumatoid Arthritis Patients With Low Disease Activity Is Feasible

    Noortje van Herwaarden1, Susan Herfkens-Hol1, Aatke van der Maas1, Bart J.F. van Den Bemt2, Ronald F. van Vollenhoven3, Johannes W.J. Bijlsma4 and Alfons A. den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, 3Karolinska Institute, Stockholm, Sweden, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Tocilizumab, at a registered dose of 8mg/kg, has proven to be effective in the treatment of rheumatoid arthritis. Clinical trial data show that a…
  • Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting

    ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis

    Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan

    a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
  • Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting

    Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX

    Toshihisa Kojima1, Nobunori Takahashi2, Koji Funahashi3, Shuji Asai1, Masahiro Hanabayashi1, Shinya Hirabara4, Nobuyuki Asai5 and Naoki Ishiguro2, 1Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 2Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 5Nagoya Univeristy Hospital, Nagoya, Japan

    Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…
  • Abstract Number: 1437 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes At Two Years and The Effect Of Tocilizumab Discontinuation Following Sustained Remission In The Second Year Of The ACT-RAY Study

    Thomas W.J. Huizinga1, Philip G. Conaghan2, Emilio Martin-Mola3, Georg Schett4, Howard Amital5, Ricardo M. Xavier6, Orrin Troum7, Maher Aassi8, Corrado Bernasconi9 and Maxime Dougados10, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 4Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5The Zabludowicz Center For Autoimmune Diseases, and Department of Medicine 'B',, Sheba Medical Center,Tel-Hashomer, Tel-Aviv University, Tel-hashomer, Israel, 6Rheumatology Division, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul - Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 7University of Southern California School of Medicine, Santa Monica, CA, 8F. Hoffmann-La Roche, Basel, Switzerland, 9Consultant, Basel, Switzerland, 10Cochin Hospital, Paris, France

    Background/Purpose: 24- and 52- week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO])…
  • Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting

    Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs

    Sang Jin Lee1,2, Kyung Rok Kim3, Sang Hyun Joo3, Jae Myung Lee3, In Ah Choi3, Joo Youn Lee2, Hyun Jung Yoo2, Eun Young Lee4, Eun Bong Lee1, Won Park5, Sung Hwan Park6, Seung-Cheol Shim7, Dae-Hyun Yoo8, Han Joo Baek9, Hyun Ah Kim10, Soo Kon Lee11, Yun Jong Lee1, Young Eun Park12, Hoon-Suk Cha13 and Yeong Wook Song2,3, 1Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, 2Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 4Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, 7Medicine, Rheumatology, Eulji University, Daejeon, South Korea, 8Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, 10Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, 11Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 12Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, 13Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.